FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug

FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug

FDA & Regulatory Intelligence, FDA & Regulatory Intelligence, Pharma Market Case Studies, Pharma News / Leave a Comment

FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Breaking Case Study FDA & Regulatory Intelligence Witfire Elite View FTX-6058 and Pociredir FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug FTX-6058 and Pociredir showed strong early sickle […]

FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug Read More »

IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion

IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion

Pharma Market Case Studies, Pharma News / Leave a Comment

IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View IQVIA Wegovy Pill Data Oral GLP-1 May Bring New Patients Into the Market IQVIA’s early Wegovy pill data suggests oral GLP-1 drugs may expand the obesity

IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion Read More »

Fulcrum’s Pociredir Collapse How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug

Fulcrum’s Pociredir Collapse: How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug

Pharma Market Case Studies, Pharma News / Leave a Comment

Fulcrum’s Pociredir Collapse: How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Breaking Case Study FDA & Regulatory Intelligence Witfire Elite View Fulcrum’s Pociredir Collapse How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug A data-heavy Witfire Breaking Case

Fulcrum’s Pociredir Collapse: How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug Read More »

Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk

Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk

Investments / Leave a Comment

Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk | Witfire Elite View Witfire Elite Investment Case Studies Strategy Investment News Investment Witfire Elite View Lilly’s Germany Investment Cut Why Pharma Capital Is Starting to Vote Against Policy Risk Eli Lilly is reportedly halving its planned €2.3 billion Germany investment,

Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk Read More »

Philippines AI Liver Cancer Breakthrough How the CANDLE Study Could Change Early Detection

Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection

Pharma News, Philippines Pharma Watch / Leave a Comment

Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection | Witfire Elite View Witfire Elite Philippines Pharma Watch Case Studies Strategy Breaking Analysis Philippines Pharma Watch Witfire Elite View Philippines AI Liver Cancer Breakthrough How the CANDLE Study Could Change Early Detection A Witfire Breaking Analysis on how the Philippines’ CANDLE

Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection Read More »

IQVIA Signal Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections

IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections

FDA & Regulatory Intelligence, Pharma Market Case Studies, Pharma News / Leave a Comment

IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections A data-rich pharma case study on how IQVIA’s early

IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections Read More »

FDA’s Digital Liver Break How AI Toxicology Could Change Drug Development Before Phase I

FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I

FDA & Regulatory Intelligence, Pharma Market Case Studies, Pharma News / Leave a Comment

FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence Witfire Elite View FDA’s Digital Liver Break How AI Toxicology Could Change Drug Development Before Phase I FDA accepted the first in silico

FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I Read More »

The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China

The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China

Pharma Market Case Studies, Pharma News / Leave a Comment

The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The China Biotech Pipeline Grab How Big Pharma Started Buying Innovation From China A data-heavy pharma case study on how Pfizer, BMS,

The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China Read More »

The Pharma Tariff War How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy

The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy

Pharma News, Stock Market / Leave a Comment

The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Study Witfire Elite View The Pharma Tariff War How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy A

The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy Read More »

Scroll to Top